A quinoxaline 1,4-di-N-oxide derivative induces DNA oxidative damage not attenuated by vitamin C and E treatment

Chemico-Biological Interactions

Volumn 168, Issue 2, 2007, Pages 95-105

  Azqueta, Amaia ^a   Arbillaga, Leire ^a   Pachón, Gisela ^b   Cascante, Marta ^b   Creppy, Edmond E ^c   Cerain, Adela López de ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Bioreductive agent; Caco 2 cells; Comet assay; DNA oxidative damage; Quinoxalines; Vitamin C; Vitamin E

Indexed keywords

7 CHLORO 3 [[(N,N DIMETHYLAMINO)PROPYL]AMINO] 2 QUINOXALINECARBONITRILE 1,4 DI N OXIDE HYDROCHLORIDE; ALPHA TOCOPHEROL; ASCORBIC ACID; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; ENDONUCLEASE III; ENZYME; PURINE; PYRIMIDINE; QUINOXALINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CELL PROTECTION; COMET ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; HUMAN; HUMAN CELL; HYPOXIA; OXIDATIVE STRESS;

ANOXIA; ASCORBIC ACID; CACO-2 CELLS; DNA DAMAGE; DNA GLYCOSYLASES; DNA-FORMAMIDOPYRIMIDINE GLYCOSYLASE; HUMANS; PRODRUGS; QUINOXALINES; REACTIVE OXYGEN SPECIES; VITAMIN E;

EID: 34250196512     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.02.013     Document Type: Article

References (56)

1. Denny W.A. The role of hypoxia-activated prodrugs in cancer therapy. Oncology 1 (2000) 25-29
2. Denny W.A. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36 (2001) 577-595
3. Kennedy K.A., Teicher B.A., Rockwell S., and Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol. 29 (1980) 1-8
4. Brown J.M., and Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58 (1998) 1408-1416
5. Brown J.M. The hypoxic cell: a target for selective cancer therapy-18th Bruce F. Cain memorial award lecture. Cancer Res. 59 (1999) 5863-5870
6. Brown J.M. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today 6 (2000) 157-161
7. Villa M.A. La radioterapia en relación con la hipoxia tumoral y la anemia. Radiobiología 1 (2001) 7-8
8. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem. Biophys. Res. Commun. 299 (2002) 676-680
9. Wouters B.G., Weppler S.A., Koritzinsky M., Landuyt W., Nuyts S., Theys J., Chiu R.K., and Lambin P. Hypoxia as a target for combined modality treatments. Eur. J. Cancer 38 (2002) 240-257
10. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., and Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
11. Hockel M., Schlenger K., Hockel S., and Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59 (1999) 4525-4528
12. Lin A.J., Cosby L.A., Shansky C.W., and Sartorelli A.C. Potential bioreductive alkylating agents. Part 1. Benzoquinone derivatives. J. Med. Chem. 15 (1972) 1247-1252
13. Rauth A.M., Melo T., and Misra V. Bioreductive therapies: an overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42 (1998) 755-762
14. Brown J.M., and Koong A.J. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J. Natl. Cancer Inst. 83 (1991) 178-185
15. Kovacs M.S., Hocking D.J., Evans J.W., Siim B.G., Wouters B.G., and Brown J.M. Cisplatin anti-tumor potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer 80 (1999) 1245-1251
16. Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., and Lee W.W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12 (1986) 1239-1242
17. Elwell J.H., Siim B.G., Evans J.W., and Brown J.M. Adaptation of human tumour cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic toxicity. Biochem. Pharmacol. 54 (1997) 249-257
18. Biedermann K.A., Wang J., Graham R.P., and Brown J.M. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer 63 (1991) 358-362
19. Wang J., Biedermann K.A., and Brown J.M. Repair of DNA and chromosome breaks in cells exposed to SR-4233 under hypoxia or to ionizing radiation. Cancer Res. 52 (1992) 4473-4477
20. Siim B.G., van Zijl P.L., and Brown J.M. Tirapazamine-induced DNA damage measured using the comet assay correlates with toxicity towards hypoxic tumour cells in vitro. Br. J. Cancer 73 (1996) 952-960
21. Daniels J.S., and Gates K.S. Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol. 11 (1998) 1254-1257
22. Kotandeniya D., Ganley B., and Gates K.S. Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). Bioorg. Med. Chem. Lett. 12 (2002) 2325-2329
23. Henessey T.D., and Edwards J.R. Antibacterial properties of quindoxin. New growth-promoting agent. Vet. Rec. 90 (1972) 187-191
24. Suter W., Rosselet A., and Knüsel F. Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob. Agents Chemother. 13 (1978) 770-783
25. Voogd C.E., Van der Stel J.J., and Jacobs J.J. The mutagenic action of quindoxin, carbadox, olaquindox and some other N-oxides on bacteria and yeast. Mutat. Res. 78 (1980) 233-242
26. Nunoshiba T., and Nishioka H. Genotoxicity of quinoxaline 1,4-dioxide derivatives in Escherichia coli and Salmonella typhimurium. Mutat. Res. 217 (1989) 203-209
27. Tucker M.J. Carcinogenic action of quinoxaline 1,4-dioxide in rats. J. Natl. Cancer Inst. 55 (1975) 137-146
28. Ganley B., Chowdhury G., Bhansali J., Daniels J.S., and Gates K.S. Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxides. Bioorg. Med. Chem. 9 (2001) 2395-2401
29. Monge A., Palop J.A., López de Cerain A., Senador V., Martinez-Crespo F.J., Sainz Y., Narro S., García E., de Miguel C., González M., Hamilton E., Barker E., Clarke E.D., and Greenhow D.T. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides. J. Med. Chem. 38 (1995) 1786-1792
30. Monge A., Martinez-Crespo F.J., López de Cerain A., Palop J.A., Narro S., Senador V., Marín A., Sainz Y., González M., Hamilton E., and Barker A.J. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. J. Med. Chem. 38 (1995) 4488-4494
31. Ortega M.A., Morancho M.J., Martínez-Crespo F.J., et al. New quinoxalinecarbonitrile 1,4-di-N-oxides derivates as hypoxic-cytotoxic agents. Eur. J. Med. Chem. 35 (2000) 21-30
32. Gali-Muhtasib H.U., Haddadin M.J., Rahhal D.N., and Younes I.H. Quinoxaline 1,4-dioxides as anticancer hypoxia-selective drugs. Oncol. Rep. 8 (2001) 679-684
33. Diab-Assef M., Haddadin M.J., Yared P., Assad C., and Gali-Muhtasib H.U. Quinoxaline 1,4-dioxides: hypoxia-Selective therapeutic agents. Mol. Carcin. 33 (2002) 198-205
34. Azqueta A., Pachón G., Cascante M., Creppy E., Monge A., and López de Cerain A. Selective toxicity of a quinoxaline 1,4-di-N-oxide derivate in human tumoral cell lines. Arzneim.-Forsch. (Drug Res.) 55 (2005) 177-182
35. Azqueta A., Pachón G., Cascante M., Creppy E., and López de Cerain A. DNA damage induced by a quinoxaline 1,4-di-N-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay. Mutagenesis 20 (2005) 165-171
36. Collins A.R., Duthie S.J., and Dobson V.L. Direct enzymatic detection of endogenous base damage in human lymphocyte DNA. Carcinogenesis 14 (1993) 1733-1735
37. Zamalloa E., Aldana I., Bachiller C.M., and Monge A. Physico-chemical properties and stability of the new hypoxia-selective agent 7-chloro-3-[[(N,N,-dimethylamino)propyl]amino]-2-quinoxalinecarbonitrile 1,4-di-N-oxide hydrochloride. Arzneim.-Forsch. (Drug Res.) 47 (1997) 873-878
38. Singh N.P., McCoy M.T., Tice R.R., and Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell. Res. 175 (1988) 184-191
39. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., and Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35 (2000) 206-221
40. Wang H., and Joseph J.A. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic. Biol. Med. 27 (1999) 612-616
41. Borek C. Dietary antioxidants and human cancer. Integr. Cancer Ther. 3 (2004) 333-341
42. David-Cordonnier M.-H., Laval J., and O'Neill P. Clustered DNA damage, influence on damage excision by XRS5 nuclear extracts and Escherichia coli Nth and Fpg proteins. J. Biol. Chem. 275 (2000) 11865-11873
43. Boiteux S., Gajewski E., Laval J., and Dizdaroglu M. Substrate specificity of the Escherichia coli Fpg protein (formamidopyrimidine-DNA glycosylase): excision of purine lesions in DNA produced by ionizing radiation or photosensitization. Biochemistry 31 (1992) 106-110
44. Tchou J., Kasai H., Shibutani S., Chung M.H., Laval J., Grollman A.P., and Nishimura S. 8-Oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 4690-4694
45. Doetsch P.W., Henner W.D., Cunningham R.P., Toney J.H., and Helland D.E. A highly conserved endonuclease activity present in Escherichia coli, bovine, and human cells recognizes oxidative DNA damage at sites of pyrimidines. Mol. Cell. Biol. 7 (1987) 26-32
46. Chowdhury G., Delshanee K., Daniels J.S., Barnes C.H., and Gates K.S. Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide. Chem. Res. Toxicol. 17 (2004) 1399-1405
47. Lloyd R.V., Duling D.R., Rumyantseva G.V., Mason R.P., and Bridson P.K. Microsomal reduction of 3-amino-1,2,4-benzotrizine 1,4-dioxide to a free radical. Mol. Pharmacol. 40 (1991) 440-445
48. Herscher L.L., Murali C.K., Cook J.A., Coleman C.N., Biaglow J.E., Tuttle S.W., Gonzalez F.J., and Mitchell J.B. Int. J. Radiat. Oncol. Biol. Phys. 30 (1994) 879-885
49. B. Halliwell. Vitamin C: antioxidant or prooxidant in vivo? Free Radic. Res. 25 (1996) 439-454.
50. Rehman A., Collins C.S., Yang M., Kelly M., Diplock A.T., Halliwell B., and Rice-Evans C. The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. Biochem. Biophys. Res. Commun. 246 (1998) 293-298
51. Carr A., and Frei B. Does vitamin C act as a pro-oxidant under physiological conditions?. FASEB J. 13 (1999) 1007-1024
52. Wolf R., Wolf D., and Ruocco V. Vitamin E: the radical protector. J. Eur. Acad. Dermatol. Venereol. 10 (1998) 103-117
53. MacEvilly C., and Muller D. Lipid peroxidation in neural tissues and fractions from vitamin E deficient rats. Free Radic. Biol. Med. 20 (1966) 639-648
54. Bisby R.H., Johnson S.A., and Parker A.W. Quenching of reactive oxidative species by probucol and comparison with other antioxidants. Free radic. Biol. Med. 20 (1996) 411-420
55. Yamasita N., Murata M., Inoue S., Burkitt M.J., Milne S., and Kawanishi S. α-Tocopherol induces oxidative damage to DNA in the presence of copper (II) ions. Chem. Res. Toxicol. 11 (1988) 855-862
56. Traber M.G., and Sies H. Vitamin E in humans: demand and delivery. Ann. Rev. Nutr. 16 (1996) 321-347